Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)

Recursion Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $448.3 million for Q1 2021.

• Quarterly Preferred Stock Liabilities rose 122.92% year-over-year to $448.3 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $448.3 million (up 122.92% YoY) and the FY2020 annual result came in at $448.3 million, up 122.92% from the prior year.
• Preferred Stock Liabilities was $448.3 million for Q1 2021 at Recursion Pharmaceuticals, roughly flat from $448.3 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $448.3 million in Q4 2020 and bottomed at $201.1 million in Q1 2020.